2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
July 31, 2013
Article
Measurable patient characteristics that predict better tolerance have not been widely studied and are desperately needed in clinical practice to inform treatment decision-making and individualize care for each older adult with AML.
July 25, 2013
Video
Bayard L. Powell, MD, the Director-At-Large and a Professor in Hematology & Oncology at the Wake Forest Baptist Medical Center Comprehensive Cancer Center, discusses the next steps for CPI-613 in hematologic malignancies.
July 16, 2013
Article
Alterations in the chromosomes of two genes have been implicated in an increased risk of prostate cancer mortality, and the discovery holds promise for distinguishing which patients are candidates for more aggressive therapy.
June 11, 2013
Video
Bayard L. Powell, MD, from the Wake Forest Baptist Medical Center Comprehensive Cancer Center, discusses a phase I study that explored the first-in-class mitochondrial metabolism inhibitor CPI-613 in patients with advanced hematologic malignancies.
April 18, 2013
Article
Perry Shen, MD, FACS, and Clancy Clark, MD, from Wake Forest Baptist Health Comprehensive Cancer Center, discuss advances in the management of hepatic and pancreatic malignancies.